Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (430)	1/18/1999 1:20:00 PM
From: Russian Bear	Read Replies (1) \| Respond to of 1073

Rick, Your "...no question too dumb..." post could not have come at a more opportune time for me. <g> In that spirit: What do you, or other thread participants, think of Maxim Pharmaceuticals (MMP)? Their lead product, Maxamine, in combination with IL-2, is currently in PIII for acute myelogenous leukemia and malignant melanoma, and in PI/II for several other indications, including renal cell cancer and HVC (here, I believe, in combination with INF-alpha.) (It could also have applications in the large market cancers, lung and prostate.) AML PII results (length of remissions) look very impressive (at least intuitively; I wasn't able to find or calculate a p-value.) Here is the press release summary: biz.yahoo.com The MMP website, maxim.com, provides a very general (much too general, really) overview. Insiders, it should be noted, have been selling: biz.yahoo.com One final note: MMP's cash position might be of some concern, unless they find a corporate partner, and relatively soon. Also, MMP's price/book is approx. 4-5, which might make it a tad rich for this thread. Thanks, as always, RB

To: scaram(o)uche who wrote (430)	1/18/1999 1:41:00 PM
From: JZGalt	Respond to of 1073

Goes with the saying: There are no dumb questions, only dumb mistakes....